Huntington’s Disease and Psychiatric Comorbidities: A Retrospective Study in Portugal

José Rocha; Carolina Soares; Manuel Gonçalves-Pinho

doi:10.20344/amp.23438

Authors

José Rocha Faculdade de Medicina. Universidade do Porto. Porto. https://orcid.org/0009-0007-3664-9433
Carolina Soares Department of Neurology. Unidade Local de Saúde São João. Porto. & RISE-Health. Department of Clinical Neurosciences and Mental Health. Faculdade de Medicina. Universidade do Porto. Porto. https://orcid.org/0000-0001-6545-1863
Manuel Gonçalves-Pinho RISE-Health. Department of Clinical Neurosciences and Mental Health. Faculdade de Medicina. Universidade do Porto. Porto. & Department of Psychiatry and Mental Health. Unidade Local de Saúde do Tâmega e Sousa. Penafiel. https://orcid.org/0000-0001-6098-429X

DOI:

https://doi.org/10.20344/amp.23438

Keywords:

Comorbidity, Hospitalization, Huntington Disease, Mental Disorders, Portugal, Routinely Collected Health Data

Abstract

Introduction: Huntington’s disease is a progressive neurodegenerative disorder characterized by motor, cognitive, and behavioral symptoms. While psychiatric comorbidity is common and may influence disease outcomes, there is a lack of data on its prevalence and impact in Portugal. This study aimed to analyze the frequency and impact of a diagnosis of psychiatric comorbidities among Huntington’s disease hospitalized patients in Portugal.
Methods: A retrospective observational study was conducted using administrative data from Portuguese public hospitals within the National Health Service between 2000 and 2016. All hospitalization episodes of patients with a diagnosis of Huntington’s disease (International Classification of Diseases, Ninth Revision, Clinical Modification code 333.4) were analyzed. Comorbid psychiatric diagnoses registered as primary or secondary diagnoses were identified and defined using the Clinical Classification Software codes 650-670. Age at admission, length of hospital stay, admission type, in-hospital mortality, and estimated hospital charges were analyzed according to psychiatric comorbidity categories and adjusting for age and sex.
Results: A total of 1667 hospitalizations with a diagnosis of Huntington’s disease occurred between 2000 and 2016, of which 28.97% had a psychiatric comorbidity. These patients were more likely to be younger (adjusted odds ratio = 1.32, 95% confidence interval 1.07 - 1.64; p = 0.011) and to have longer hospitalizations (adjusted odds ratio = 1.88, 95% confidence interval 1.52 - 2.34; p < 0.001) than those with no psychiatric comorbidity. No association was found between psychiatric comorbidity in general and in-hospital mortality, admission type or hospitalization costs. An upward trend was observed in Huntington’s disease admissions and the percentage of those with psychiatric comorbidity over the study period.
Conclusion: Psychiatric comorbidity in Huntington’s disease was associated with younger age at admission and longer hospitalizations. These results highlight the importance of psychiatric care in the management of these patients. Early screening and intervention could improve outcomes and optimize healthcare resource allocation.

Downloads

Download data is not yet available.

References

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.

McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25:24-34.

Costa MD, Magalhães P, Guimarães L, Maciel P, Sequeiros J, Sousa A. The CAG repeat at the Huntington disease gene in the Portuguese population: insights into its dynamics and to the origin of the mutation. J Hum Genet. 2006;51:189-95.

Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, et al. A biological classification of Huntington’s disease: the integrated staging system. Lancet Neurol. 2022;21:632-44.

Rosenblatt A. Neuropsychiatry of Huntington’s disease. Dialogues Clin Neurosci. 2007;9:191-7.

Ishihara L, Oliveri D, Wild EJ. Neuropsychiatric comorbidities in Huntington’s and Parkinson’s Disease: a United States claims database analysis. Ann Clin Transl Neurol. 2021;8:126-37.

Watt DC, Seller A. A clinico-genetic study of psychiatric disorder in Huntington’s chorea. Psychol Med. 1993;23:S1-46.

Cummings JL. Behavioral and psychiatric symptoms associated with Huntington’s disease. Adv Neurol. 1995;65:179-86.

Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington’s disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci. 2014;8:135.

Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:219-26.

Kingma EM, van Duijn E, Timman R, van der Mast RC, Roos RA. Behavioural problems in Huntington’s disease using the problem behaviours assessment. Gen Hosp Psychiatry. 2008;30:155-61.

Berrios GE, Wagle AC, Marková IS, Wagle SA, Ho LW, Rubinsztein DC, et al. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington’s disease gene carriers. Psychiatry Res. 2001;102:217-25.

Kachian ZR, Cohen-Zimerman S, Bega D, Gordon B, Grafman J. Suicidal ideation and behavior in Huntington’s disease: systematic review and recommendations. J Affect Disord. 2019;250:319-29.

Walker FO. Huntington’s disease. Lancet. 2007;369:218-28.

Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188:372-6.

Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC. Suicidality in Huntington’s disease. J Affect Disord. 2012;136:550-7.

McGarry A, McDermott MP, Kieburtz K, Fung WL, McCusker E, Peng J, et al. Risk factors for suicidality in Huntington disease: an analysis of the 2CARE clinical trial. Neurology. 2019;92:e1643-51.

Connors MH, Teixeira-Pinto A, Loy CT. Psychosis and longitudinal outcomes in Huntington disease: the COHORT Study. J Neurol Neurosurg Psychiatry. 2020;91:15-20.

Jaini A, Yomtoob J, Yeh C, Bega D. Understanding HD psychosis: an analysis from the ENROLL-HD database. Tremor Other Hyperkinet Mov. 2020;10:16.

Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12:e1001885.

Ministério da Saúde de Portugal. Portaria n.º 132/2009. Diário da República, I Série, n.º 21 (2009/01/30). p 660-758.

Vicente E, Ruiz de Sabando A, García F, Gastón I, Ardanaz E, Ramos-Arroyo MA. Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain. Orphanet J Rare Dis. 2021;16:77.

Peball M, Heim B, Ellmerer P, Frank F, Busin N, Galffy M, et al. Hospital admissions of Huntington’s disease patients in a huntington’s disease centre between 2011 and 2016: a retrospective analysis. Mov Disord Clin Pract. 2022;9:628-36.

Almeida J, Xavier M, Cardoso G, Gonçalves Pereira M, Gusmão R, Barahona Correa B, et al. Estudo epidemiológico nacional de saúde mental. 1.º Relatório. 2013. [cited 2025 Feb 01]. Available from: https://www.mgfamiliar.net/wp-content/uploads/Relatorio_Estudo_Saude-Mental_2.pdf.

Freitas A, Lema I, da Costa-Pereira A, editors. Comorbidity coding trends in hospital administrative databases. New advances in information systems and technologies. Cham: Springer International Publishing; 2016.

Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H. Epidemiology and health care utilization of patients suffering from Huntington’s disease in Germany: real world evidence based on German claims data. BMC Neurol. 2019;19:318.

Le Strat Y, Grant BF, Ramoz N, Gorwood P. A new definition of early age at onset in alcohol dependence. Drug Alcohol Depend. 2010;108:43-8.

Mendizabal A, Diaz JM, Bustamante AV, Bordelon Y. Health services in Huntington disease: a systematic literature review. Neurol Clin Pract. 2023;13:e200108.